94E.F

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$0	—	$-0.81	$-0.81–$-0.81	—	1
2027	$19M	—	$-0.74	$-0.74–$-0.74	—	1
2028	$0	-100.0%	$-0.89	$-0.89–$-0.89	—	1
2029	$0	—	$-1.13	$-1.13–$-1.13	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 2 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-13	$-0.17	$-0.18	-9.8%
2026-05-07	$-0.15	$-0.19	-26.6%
2026-03-23	$-0.17	$-0.42	-149.7%
2025-11-13	$-0.16	$-0.18	-11.0%
2025-08-14	$-0.16	$-0.14	+9.9%
2025-05-08	$-0.15	$-0.17	-16.5%
2025-03-25	$-0.15	$-0.15	+2.5%
2024-11-07	$-0.12

DCF fair valuemodel estimate

Intrinsic value

$0.99

Price

$4.44

Implied downside

-78%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
94E.FZura Bio Limited	$4.44	-3.06%	$422M	—
2LYA.FHigh Tide Inc.	$2.19	+1.63%	$192M	—
6H90.SGHealwell AI Inc	$0.48	+2.92%	$144M	—
88Q.DE4basebio PLC	$5.45	+0.00%	$84M	—
BNN.DEBRAIN Biotech AG	$2.78	-0.36%

Zura Bio Limited

Zura Bio Limited, a biotechnology firm in the clinical stage, is focused on creating and advancing novel therapeutic solutions for immune-related and inflammatory conditions. The company's portfolio includes ZB-168, an anti-IL7Rα inhibitor developed to modulate diseases influenced by the IL7 and TSLP biological pathways. Additionally, they are progressing with Torudokimab, a monoclonal antibody specifically designed to neutralize IL33, which is presently in Phase 2 clinical trials. Zura Bio Limited operates out of San Diego, California.

zurabio.com

Employees: 40
IPO / List date: Mar 21, 2023
HQ: US

Held by traders on TradeandTell

No one on the platform currently holds 94E.F.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in 94E.F as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded 94E.F yet.